17.91
-0.16 (-0.89%)
| Previous Close | 18.07 |
| Open | 18.03 |
| Volume | 853,893 |
| Avg. Volume (3M) | 1,227,415 |
| Market Cap | 2,028,314,496 |
| Price / Sales | 438.12 |
| Price / Book | 3.53 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2026 |
| Operating Margin (TTM) | -1,525.50% |
| Diluted EPS (TTM) | -3.01 |
| Quarterly Revenue Growth (YOY) | 184.40% |
| Total Debt/Equity (MRQ) | 1.55% |
| Current Ratio (MRQ) | 10.49 |
| Operating Cash Flow (TTM) | -152.68 M |
| Levered Free Cash Flow (TTM) | -117.16 M |
| Return on Assets (TTM) | -33.54% |
| Return on Equity (TTM) | -69.21% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Immunome, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | 1.5 |
| Price Volatility | 1.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -0.50 |
|
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 11.48% |
| % Held by Institutions | 83.28% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Redmile Group, Llc | 31 Mar 2026 | 5,558,885 |
| Enavate Sciences Gp, Llc | 31 Mar 2026 | 3,613,799 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BIENAIME JEAN JACQUES | 18.58 | 18.58 | 0 | 0 |
| Aggregate Net Quantity | 0 | |||
| Aggregate Net Value ($) | 0 | |||
| Aggregate Avg. Buy ($) | 18.58 | |||
| Aggregate Avg. Sell ($) | 18.58 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| BIENAIME JEAN JACQUES | Director | 05 Jun 2026 | Sell (-) | 10,500 | 18.58 | 195,090 |
| BIENAIME JEAN JACQUES | Director | 05 Jun 2026 | Buy (+) | 10,500 | 18.58 | 195,090 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |